Børsen.dk | 11. Maj 2018 | ~ Tidligere Zealand-chef ude af amerikansk biotekselskab efter private køb med firmakort ~ | (In English:) - David Horn Solomon, (former) Chief Executive Officer (CEO) at Akari Therapeutics (NASDAQ:AKTX), resigns after personal charges on company credit card, while the CEO of Ambu A/S, Lars Marcher, is able to snatch, DKK 500 million on option programs (besides his normal salary) .. | Blogger: 💸The Big Pharma SCAM!!! 💸 ... Who is Akari Therapeutics, Plc? A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases ... Who is Ambu A/S? A Danish company that develops, produces, and markets diagnostic and life-supporting equipment and solutions to hospitals and rescue services... |

David Solomon nåede kun at være topchef i Akari Therapeutics i otte måneder

LÆS VIDERE: http://borsen.dk/nyheder/virksomheder/artikel/1/362669/tidligere_zealand-chef_ude_af_amerikansk_biotekselskab_efter_private_koeb_med_firmakort.html
https://www.bt.dk/erhverv/tidligere-topchef-fratraeder-prompte-brugte-firmaets-kreditkort-til-personlige
https://finans.dk/erhverv/ECE10588304/ambudirektoer-lars-marcher-staar-til-at-score-over-500-mio-kr-paa-optionsprogrammer-storinvestor-siger-fra/?articleId=10588304&ctxref=ext